Contineum Therapeutics Reports Q3 GAAP EPS of -$0.49
Contineum Therapeutics (CTNM) has released its third-quarter financial results, reporting a GAAP earnings per share (EPS) loss of $0.49. As of September 30, 2026, the company maintained a strong liquidity position with cash, cash equivalents, and marketable securities totaling $244.5 million. The report follows market volatility regarding the company's clinical progress, specifically concerning results for admilparant in treating Idiopathic Pulmonary Fibrosis (IPF). Investors are closely monitoring how these clinical outcomes and current burn rates will influence the company's long-term valuation.
Tickers: $CTNM